199 related articles for article (PubMed ID: 15100500)
21. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).
Van den Abbeele AD; Badawi RD
Eur J Cancer; 2002 Sep; 38 Suppl 5():S60-5. PubMed ID: 12528774
[TBL] [Abstract][Full Text] [Related]
22. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
[TBL] [Abstract][Full Text] [Related]
23. Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging.
Zincirkeser S; Sevinc A; Kalender ME; Camci C
World J Gastroenterol; 2007 Apr; 13(15):2261-2. PubMed ID: 17465516
[TBL] [Abstract][Full Text] [Related]
24. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
Choi H; Charnsangavej C; de Castro Faria S; Tamm EP; Benjamin RS; Johnson MM; Macapinlac HA; Podoloff DA
AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
[TBL] [Abstract][Full Text] [Related]
25. [Early response to treatment with Glivec detected with 18F-FDG PET in a patient with gastrointestinal stromal tumor].
Delgado Bolton RC; Ortega Candil A; Pérez Castejón MJ; Garcerant M; Cabrera Martín MN; Lapeña Gutiérrez L; Carreras Delgado JL
Rev Esp Med Nucl; 2008; 27(2):112-7. PubMed ID: 18367049
[TBL] [Abstract][Full Text] [Related]
26. FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.
Malle P; Sorschag M; Gallowitsch HJ
Wien Med Wochenschr; 2012 Oct; 162(19-20):423-9. PubMed ID: 22890522
[TBL] [Abstract][Full Text] [Related]
27. Gastrointestinal stromal tumors: chemotherapy and imatinib.
Muler JH; Baker L; Zalupski MM
Curr Oncol Rep; 2002 Nov; 4(6):499-503. PubMed ID: 12354362
[TBL] [Abstract][Full Text] [Related]
28. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
Abhyankar SA; Nair N
Clin Nucl Med; 2008 Mar; 33(3):213-4. PubMed ID: 18287851
[No Abstract] [Full Text] [Related]
29. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
Fuster D; Ayuso JR; Poveda A; Cubedo R; Casado A; Martínez-Trufero J; López-Pousa A; Del Muro XG; Lomeña F; Maurel J; Pons F
Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):680-7. PubMed ID: 21150863
[TBL] [Abstract][Full Text] [Related]
30. Esophageal gastrointestinal stromal tumor: report of 7 patients.
Shinagare AB; Zukotynski KA; Krajewski KM; Jagannathan JP; Butrynski J; Hornick JL; Ramaiya NH
Cancer Imaging; 2012 Apr; 12(1):100-8. PubMed ID: 22542728
[TBL] [Abstract][Full Text] [Related]
31. FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment.
Nakajo M; Jinnouchi S; Inoue H; Otsuka M; Matsumoto T; Kukita T; Tanabe H; Tateno R; Nakajo M
Clin Nucl Med; 2007 Oct; 32(10):775-8. PubMed ID: 17885356
[TBL] [Abstract][Full Text] [Related]
32. Early Evaluation of Response Using
Farag S; Geus-Oei LF; van der Graaf WT; van Coevorden F; Grunhagen D; Reyners AKL; Boonstra PA; Desar I; Gelderblom H; Steeghs N
J Nucl Med; 2018 Feb; 59(2):194-196. PubMed ID: 28970330
[No Abstract] [Full Text] [Related]
33. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib.
Shinto A; Nair N; Dutt A; Baghel NS
Clin Nucl Med; 2008 Jul; 33(7):486-7. PubMed ID: 18580237
[TBL] [Abstract][Full Text] [Related]
34. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
[TBL] [Abstract][Full Text] [Related]
35. Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate.
Reichardt P; Schneider U; Stroszczynski C; Pink D; Hohenberger P
J Clin Pathol; 2004 Feb; 57(2):215-7. PubMed ID: 14747457
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
Montemurro M; Cioffi A; Dômont J; Rutkowski P; Roth AD; von Moos R; Inauen R; Toulmonde M; Burkhard RO; Knuesli C; Bauer S; Cassier P; Schwarb H; Le Cesne A; Koeberle D; Bärtschi D; Dietrich D; Biaggi C; Prior J; Leyvraz S
Cancer; 2018 Apr; 124(7):1449-1454. PubMed ID: 29315500
[TBL] [Abstract][Full Text] [Related]
37. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors.
Otomi Y; Otsuka H; Morita N; Terazawa K; Furutani K; Harada M; Nishitani H
J Med Invest; 2010 Aug; 57(3-4):270-4. PubMed ID: 20847527
[TBL] [Abstract][Full Text] [Related]
38. Management of malignant gastrointestinal stromal tumours.
Joensuu H; Fletcher C; Dimitrijevic S; Silberman S; Roberts P; Demetri G
Lancet Oncol; 2002 Nov; 3(11):655-64. PubMed ID: 12424067
[TBL] [Abstract][Full Text] [Related]
39. F-18 FDG PET for assessing tyrosine kinase-related signal transduction inhibition in a GIST c-kit-positive tumor patient by imatinib.
Zaknun JJ; Kendler D; Moncayo R; zur Nedden D; Virgolini I
Clin Nucl Med; 2005 Nov; 30(11):749-51. PubMed ID: 16237304
[No Abstract] [Full Text] [Related]
40. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.
Pantaleo MA; Nicoletti G; Nanni C; Gnocchi C; Landuzzi L; Quarta C; Boschi S; Nannini M; Di Battista M; Castellucci P; Fanti S; Lollini PL; Bellan E; Castelli M; Rubello D; Biasco G
J Exp Clin Cancer Res; 2010 Dec; 29(1):173. PubMed ID: 21192792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
